Identification of New Dual PDE4/5 Inhibitors Using Pharmacophore Based Virtual Screening

Authors

  • Catrina Ting En Faculty of Pharmaceutical Sciences, UCSI University, Taman Connaught, Cheras, Kuala Lumpur 56000, Malaysia
  • Anand Gaurav [1]Faculty of Pharmaceutical Sciences, UCSI University, Taman Connaught, Cheras, Kuala Lumpur 56000, Malaysia. [2]Department of Pharmaceutical Sciences, School of Health Sciences and Technology, UPES, Dehradun 248007, Uttarakhand, India. [3]Faculty of Health Sciences, Villa College, QI Campus, RahdhebaiHingun, Male' 20373, Republic of Maldives
  • Vertika Gautam Faculty of Pharmaceutical Sciences, UCSI University, Taman Connaught, Cheras, Kuala Lumpur 56000, Malaysia

DOI:

https://doi.org/10.5530/ctbp.2023.4s.85

Keywords:

dual inhibitors, pharmacophore-based, virtual screening, COPD, inflammation of mucosal layer

Abstract

Chronic Obstructive Pulmonary Disease (COPD) is a progressive airway obstruction disease caused due to inflammation of the airway mucosal layer. Current therapies have proved to be inadequate and thus there is high unmet medical need. Research has provided evidence that dual inhibition of Phosphodiesterase 4/5 (PDE4/5) is an effective strategy in suppressing inflammatory mediator release from cell types which express PDE4 and PDE5.

Read More . . .

3D presentation of the interaction between UNPD192494 (dark grey) and PDE 4 protein structure (PDB: IXMU) using Discovery Studio software.

Downloads

Published

13-12-2023

How to Cite

En, C. T., Gaurav, A., & Gautam, V. (2023). Identification of New Dual PDE4/5 Inhibitors Using Pharmacophore Based Virtual Screening. Current Trends in Biotechnology and Pharmacy, 17(4A (Supplement), 15–21. https://doi.org/10.5530/ctbp.2023.4s.85

Issue

Vol. 17 No. 4A (Supplement) (2023): Current Trends in Biotechnology and Pharmacy

Section

Research Paper